Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03962647 · ClinicalTrials.gov registry record · Early Phase 1
A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer
A Early Phase 1 study, sponsored by Vanderbilt-Ingram Cancer Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 31
- Enrollment target
NCT03962647 is a Early Phase 1 study that has completed, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 31 participants.
The verdict
NCT03962647, a Early Phase 1 study, has completed, sponsored by Vanderbilt-Ingram Cancer Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
This is a neoadjuvant study to determine the feasibility and tolerability of 2 weeks of a very low carbohydrate ketogenic diet in combination with letrozole for patients with early stage operable ER+disease.
Interventions
- DRUG Letrozole
- DIETARY_SUPPLEMENT 2-Week Ketogenic Diet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2019-07-08 |
| Est. Completion | 2024-07-14 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03962647
The ClinicalTrials.gov registry entry for NCT03962647 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Letrozole is the first listed.
NCT03962647 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03962647 about?
NCT03962647 is a clinical study titled "A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer". This is a neoadjuvant study to determine the feasibility and tolerability of 2 weeks of a very low carbohydrate ketogenic diet in combination with letrozole for patients with early stage operable ER+disease.
What is the current status of trial NCT03962647?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 31 participants. The study started on 2019-07-08. Estimated completion is 2024-07-14.
What interventions are being tested in trial NCT03962647?
The interventions under investigation include: Letrozole (DRUG), 2-Week Ketogenic Diet (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03962647?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.